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preferences and seasonality are effective in reducing the risk 
of CVD, type 2 diabetes and other chronic diseases. This pa-
per summarizes the symposium presentations. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Restricting the consumption of saturated fatty acids 
(SAFA) to reduce the risk of cardiovascular disease (CVD) 
forms the basis of recent dietary fat recommendations  [1, 
2] , in spite of the disagreement about the link between 
dietary SAFA and CVD  [3–6] . Several systematic reviews, 
meta-analyses  [7, 8] and prospective cohort studies  [9] 
have questioned the link between SAFA and CVD risk. 
Recent systematic reviews, however, highlight the impor-
tance of partial replacement of SAFA by polyunsaturated 
fatty acids (PUFA) in decreasing the risk of CVD  [1, 10, 
11] . At the Federation of European Nutrition Societies 
meeting in Berlin, Germany, October 20–23, 2015 three 
experts on dietary fat and health discussed several aspects 
of current recommendations for fatty acid consumption 
to reduce the CVD risk. The symposium was hosted by 
the International Expert Movement to Improve Dietary 
Fat Quality  [12] , an initiative of the International Union 
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 Abstract 
 Limiting the saturated fatty acid (SAFA) consumption forms 
the basis of dietary fat recommendations for heart health, 
despite several meta-analyses demonstrating no link be-
tween dietary SAFA and the risk of cardiovascular disease 
(CVD). Three experts on dietary fat and health discussed the 
evidence of reducing SAFA intake at a symposium of the 
Federation of European Nutrition Societies in Berlin, 
 Germany, October 23, 2015. Ronald P. Mensink, Maastricht 
University, the Netherlands, discussed the evidence linking 
dietary fatty acids and CVD risk. He emphasized the impor-
tance of the replacement nutrient(s) when SAFA intake is re-
duced. Julie Lovegrove, University of Reading, UK, addressed 
the question of whether higher intakes of unsaturated fatty 
acids are beneficial. She discussed the replacement of SAFA 
by polyunsaturated fatty acids (PUFA) and monounsaturat-
ed fatty acids (MUFA), noting the reduction in CVD risk with 
PUFA replacement and in CVD risk markers with MUFA re-
placement of SAFA. Ursula Schwab, University of Eastern 
 Finland, Kuopio, Finland, discussed the importance of di-
etary patterns in achieving reduced risk of CVD, observing 
that several dietary patterns following the principles of a 
health-promoting diet and adapted to local customs, food 
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of Nutritional Sciences, funded by an unrestricted educa-
tion grant from Unilever NV. This paper summarizes the 
presentations of the symposium.
 Should Saturated Fat Intakes Be Reduced? 
 Media attention to recent studies questioning the link 
between the intake of SAFA and the risk of CVD has 
 increased the confusion among consumers about con-
suming SAFA-rich foods  [13, 14] . Addressing the ques-
tion of whether SAFA intakes should be reduced, Ronald 
P. Mensink, Maastricht University, the Netherlands, 
 explained that the formulation of dietary recommenda-
tions mainly relies on risk biomarkers, which are causally 
related to CVD. Although studies examining relation-
ships between SAFA intake and risk of coronary heart 
disease (CHD) are conflicting, SAFA increases low-den-
sity lipoprotein-cholesterol (LDL-C) levels compared 
with  cis -unsaturated fatty acids. Increased LDL-C is caus-
ally related to an increased CHD risk. Hence, dietary 
guidelines recommend limiting SAFA intake. The 3-way 
relationship among SAFA, LDL-C and CHD is the cause 
of consumer confusion.
 Questions about the link between dietary SAFA and 
CVD arose from the work of Siri-Tarino et al.  [9] whose 
meta-analysis of 21 prospective cohort studies concluded 
that the evidence did not support an association between 
SAFA consumption per se and an increased risk of CVD 
or CHD. In another systematic review and meta-analysis 
of 12 prospective cohort studies, de Souza et al.  [7] found 
neither significant association between SAFA consump-
tion and all-cause CVD and CHD mortality nor risk of 
ischemic stroke or type 2 diabetes. Mensink pointed out 
that the key question is the effect of nutrients that replace 
SAFA. Thus, Jakobsen et al.  [15] reported that replacement 
of 5% energy (En) from SAFA with PUFA was associated 
with a significantly reduced risk of coronary events and 
death (hazard ratio, HR 0.87, 95% CI 0.77–0.97; and HR 
0.74, 95% CI 0.61–0.89, respectively), whereas replacement 
with carbohydrates was associated with a modestly higher 
risk of coronary events (HR 1.07, 95% CI 1.01–1.14). Evi-
dence pooled from 2 large prospective cohort studies sug-
gested that isocaloric replacement of 5% SAFA with PUFA 
or monounsaturated fatty acids (MUFA) was associated 
with a significant 25 or 15% reduction in CHD risk, respec-
tively, between the highest and lowest quintiles of con-
sumption  [16] . Others have also reported that PUFA in-
take is associated with a lower risk of CHD when it replac-
es SAFA,  trans  fats or carbohydrates  [17, 18] .
 The main link between dietary fatty acids and CHD 
risk is observed from their effects on plasma or serum 
LDL-C levels. A fatty acid is considered hypercholester-
olemic when an isoenergetic exchange of carbohydrates 
in the diet for the fatty acid causes an increase in the se-
rum total cholesterol (TC) concentrations. Carbohy-
drates have arbitrarily been called ‘neutral’. Replacement 
of  trans  fatty acids or SAFA with PUFA leads to a signifi-
cant decrease in LDL-C concentrations, with the substi-
tution of  trans -MUFA by PUFA being the most favorable.
 Subsequently, Mensink questioned the best lipid bio-
marker or combination of lipid biomarkers to predict the 
risk of CHD: LDL-C, apolipoprotein B, apolipoprotein 
CIII, small dense LDL, high-density lipoprotein choles-
terol (HDL-C), apolipoprotein A1, triacylglycerols, 
TC:HDL-C, postprandial metabolism, or Lp(a)? When 
fat is replaced by carbohydrate, one result is an increase 
in the prevalence of small dense LDLs, which are associ-
ated with higher CVD risk  [19, 20] . Increasing carbohy-
drate at the expense of SAFA may not improve the serum 
lipoprotein profile as HDL-C may be reduced and triac-
ylglycerol increased  [6] . Further, the carbohydrate type 
may affect the lipid response, with refined starches and 
sugars being associated with a comparable risk of CHD as 
SAFA, but those from whole grains associated with a sig-
nificantly lower CHD risk  [16, 21] .
 Consumption of SAFA may affect other atherogenic 
pathways unrelated to lipoproteins. Examples include 
systemic inflammation, blood pressure, endothelial func-
tion, hemostatic function, insulin resistance, postpran-
dial metabolism and weight gain. However, the effects of 
dietary SAFA on these parameters yielded mixed results.
 Various SAFA behave differently, metabolically speak-
ing, which raises the question of whether to discriminate 
among them for CVD risk. Although food fats contain 
mixtures of SAFA, the predominant ones in Western di-
ets are palmitic (C16: 0) and stearic (C18: 0) acids. Dairy 
products are relatively rich in short- and medium-chain 
SAFA (C4: 0-C10: 0), while coconut and palm kernel oil 
each have relatively large amounts of lauric (C12: 0) and 
myristic (C14: 0) acids. The potency of individual longer-
chain SAFA ( ≥ C12) in raising LDL-C levels compared to 
carbohydrate diminishes from lauric acid with increasing 
chain length up to stearic acid, which generally has a neu-
tral effect on lipid and lipoprotein levels  [6] .
 Interestingly, the effects of various SAFA on markers 
of inflammation may differ from the pattern observed on 
plasma lipids. For example, when carbohydrate was re-
placed by 8% stearic acid in controlled diets consumed by 
healthy men, plasma fibrinogen and interleukin-6 levels 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f R
ea
di
ng
   
   
   
   
   
   
   
   
   
   
   
 
13
4.
22
5.
10
9.
12
0 
- 7
/1
1/
20
16
 1
1:
03
:0
7 
AM
 Recommendations for Dietary Fatty Acids Ann Nutr Metab 2016;68:249–257
DOI: 10.1159/000446865
251
were significantly increased, while the C-reactive protein 
did not increase significantly  [22] . Although others have 
reported contrasting results with dietary stearic acid 
compared with unsaturated FA and  trans  MUFA  [23] , 
these studies emphasize that knowledge on the effects of 
individual SAFA on CHD risk markers other than serum 
lipids is limited.
 The contribution of SAFA-related food matrix to the 
risk of CVD and its associated biomarkers is sometimes 
overlooked. A recent systematic review and meta-analy-
sis of the effect of cheese consumption on blood lipids, for 
example, concluded that the consumption of hard cheese 
lowers LDL-C and HDL-C when compared to butter, but 
both had comparable effects on fasting triacylglycerol 
concentrations  [24] . Others have also reported differenc-
es in CVD risk or plasma lipid levels depending on the 
food source of SAFA  [25–27] .
 In brief, Mensink noted that prospective cohort stud-
ies and randomized controlled trials can be complemen-
tary or contradictory  [28] , as illustrated by studies on an-
tioxidants  [29] , folic acid  [30] and possibly SAFA  [31] . He 
emphasized the importance of discussing the replace-
ment nutrient(s) when SAFA intake is reduced, and ob-
served that a food pattern or food is more than a single 
nutrient. Although individual SAFA are metabolized dif-
ferently, whether they affect the health differently is un-
certain. Resolving current issues will require studies with 
integrated end points or, preferably, hard end points.
 Unsaturated Fats: Are Higher Intakes Beneficial? 
 Recent reports on the global risks for disease mortality 
and disability-adjusted life years (DALYs), that is, the 
years lost due to premature mortality and disability, iden-
tified diet as the predominant contributor to mortality 
and disability from predominantly CVD, but also diabe-
tes and neoplasms  [32] . Expressed in numbers, modifi-
able dietary risks accounted for 11.3 million deaths and 
241.1 million DALYs worldwide in 2013. These data sug-
gest opportunities for effective dietary prevention poli-
cies. The question of whether higher intake of unsatu-
rated fats is beneficial to these dietary risks was addressed 
by Julie Lovegrove, University of Reading, UK.
 There is consistent evidence that partial replacement 
of dietary SAFA with PUFA significantly reduces the risk 
of CHD events and mortality  [10, 11, 16, 18] , although 
inconsistent or contradictory data have been reported in 
some secondary prevention trials  [33, 34] . In contrast, 
too few data exist to ascertain the effect of MUFA substi-
tution on CVD mortality  [11, 35] . Furthermore, dietary 
MUFA are derived from both plant (such as olive and 
rapeseed oils, nuts and seeds) and animal sources (in-
cluding meat and poultry). The food source may have an 
impact on the association between MUFA intake and 
disease incidence or mortality. A recent meta-analysis of 
32 cohort studies comparing the top vs. the bottom third 
intakes of total MUFA reported significant risk reduc-
tions ranging from 9 to 17% for all-cause and cardiovas-
cular mortality, cardiovascular events and stroke  [36] . 
However, in sub-group analysis of MUFA of mixed ori-
gin, only higher intakes of olive oil were associated with 
a reduced risk of all-cause mortality, cardiovascular 
events and stroke.
 There are 2 distinct families of PUFA, namely, ome-
ga-6 PUFA found in vegetables and vegetable oils and 
omega-3 PUFA, which include alpha-linolenic acid 
(ALA) found only in plants and eicosapentaenoic and 
docosahexaenoic acids (EPA and DHA), respectively, 
found mainly in fish and shellfish. Evidence suggests that 
higher dietary ALA and EPA/DHA consumption is asso-
ciated with significantly reduced risk of CVD and CHD 
mortalities  [37–39] , although inconsistent and contradic-
tory data have been reported  [34, 40] . The proposed 
mechanisms of action of EPA/DHA are varied and in-
clude anti-arrhythmic, anti-thrombotic and triacylglyc-
erol-lowering effects, which may be observed within 
weeks  [41–43] , while changes in heart rate and blood 
pressure may take months  [44, 45] to be visible .
 In a study on the relationship between circulating lev-
els of linoleic acid (LA), the major n-6 PUFA in food and 
plasma, and risk of total and cause-specific mortality, LA 
was associated with a 13% lower risk of total mortality 
and a 22% lower risk of CVD mortality, comparing the 
top and bottom quintiles  [46] . The investigators also re-
ported a 49% lower risk of non-arrhythmic CHD mortal-
ity across quintiles of LA, but no significant association 
with arrhythmic CHD mortality. With stratification of 
the participants on both LA and n-3 PUFA, those with the 
highest circulating levels of both types of fatty acids had 
a 54% lower risk of CVD death compared to those with 
the lowest levels. These data support the benefits of PUFA 
and CVD risk reduction.
 There is scientific consensus that high intakes of in-
dustrially produced  trans unsaturated fatty acids, mainly 
 trans -elaidic acid (18: 1 t 9), are detrimental to heart health 
 [7, 47] . It is less clear whether the  trans  fatty acids pro-
duced in ruminants via the bacterial metabolism of un-
saturated fatty acids, as found in dairy products and 
meats, are also harmful. The main  trans fatty acid found 
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in ruminant fats is vaccenic acid (18: 1 t 11), although less-
er amounts of  trans palmitoleic (C16: 1 t 9) are also pres-
ent. The latter is increasingly recognized as a biomarker 
of dairy intake, as humans are only able to endogenously 
synthesize this from vaccenic acid, which originates in 
dairy fats  [48] . Systematic reviews and studies have re-
ported that ruminant  trans fatty acids are not associated 
with CHD  [7, 49] or CVD risk markers  [50] , but other 
published reports suggested that both ruminant and in-
dustrial  trans produced from partially hydrogenated oils 
are associated with an increased CVD risk  [51–53] .
 Recent investigations on  trans -palmitoleic acid re-
ported relations between circulating levels and higher 
LDL-C, but significantly lower triacylglycerols, incident 
diabetes and atherogenic dyslipidemia  [54, 55] . Of inter-
est are findings from a German cohort of patients sched-
uled for coronary angiography in which total trans and 
 trans -palmitoleic acids in erythrocyte membranes were 
inversely associated with the risk of cardiovascular mor-
tality and sudden cardiac death  [56] . However, it is of 
particular interest that the concentrations of  trans fatty 
acids in this cohort were low compared with values in US 
populations for the same time period (0.96 ± 0.3 vs. 2.68 ± 
0.8%). Further clarity is required to establish the specific 
impact of ruminant trans on disease risk.
 CVD risk factors include both modifiable and non-
modifiable components, with diet and lifestyle contribut-
ing to modifiable factors, such as LDL-C, blood pressure, 
elevated triacylglycerols, vascular function, inflamma-
tion, obesity and diabetes  [57] . Diet modification focused 
on improving blood lipids by the partial replacement of 
SAFA intakes with unsaturated fatty acids. An early re-
view of metabolic ward studies demonstrated that isoca-
loric replacement of 5% of calories from SAFA with PUFA 
or MUFA reduced the total blood cholesterol by 0.39 and 
0.24 mmol/l, respectively, with the main reduction occur-
ring in LDL-C  [58] . There is consistent evidence from 
randomized controlled trials that replacement of SAFA 
with unsaturated fatty acid reduces lipid risk biomarkers 
 [10] .
 Jebb et al.  [59] reported that replacement of SAFA with 
MUFA or carbohydrate resulted in a significantly lower 
TC and LDL-C, but only MUFA replacement was associ-
ated with a significantly lower TC:HDL-C ratio, a clini-
cally recognized biomarker of CVD  [59, 60] . Replacing 
9.5%En from SAFA with MUFA or n-6 PUFA resulted in 
a significantly lower TC and LDL-C and TC:HDL-C ratio 
after 4 months  [61] . Several studies concluded that partial 
replacement of dietary SAFA with PUFA results in the 
greatest reduction in the risk of CVD, events and risk fac-
tors  [11, 16, 62] . In their review of substituting increasing 
levels of %En from carbohydrates with different fatty ac-
ids, Micha and Mozaffarian  [62] reported that MUFA 
and PUFA reduced the ratio of TC:HDL-C to the greatest 
extent,  trans fatty acids increased the ratio significantly, 
but SAFA had no significant effect.
 Lovegrove discussed factors other than blood lipids 
that contribute to the risk of CVD mortality, particularly 
high blood pressure. In a parallel-group study of diets rich 
in SAFA, MUFA or PUFA, consumed for 16 weeks by 
men and women with moderate CVD risk, consumption 
of MUFA-rich diet attenuated a significant increase in 
night systolic blood pressure (SBP) observed with SAFA 
 [61] . In a meta-analysis of 12 randomized controlled tri-
als on diets high (>12%En) or low ( ≤ 12%En) in MUFA 
and risk factors for obesity and CVD, Schwingshackl et 
al.  [63] reported significant reductions in systolic and di-
astolic blood pressures with diets containing >12%En 
from MUFA and significantly lower fat mass.
 Arterial stiffness, an independent predictor of CVD, is 
affected by dietary fatty acid consumption  [64] . In a study 
of men aged 45–59 years, who were followed for a mean 
of 17.8 years, higher consumption of PUFA at baseline 
was associated with significantly lower systolic and dia-
stolic blood pressures and pulse wave velocity, a measure 
of arterial stiffness, compared with men having a higher 
intake of SAFA  [65] . Additional confirmation is, how-
ever, required.
 Dietary fat may also affect insulin sensitivity in healthy 
adults. Vessby et al.  [66] reported that with diets having 
>37%En from fat, the quality of fat did not affect insulin 
sensitivity; however, in diets with <37%En from fat, the 
substitution of MUFA for SAFA significantly improved 
insulin sensitivity in healthy volunteers. However, in the 
RISCK study, volunteers with symptoms of metabolic 
syndrome who consumed diets in which SAFA were re-
placed with MUFA or carbohydrates with high or low 
glycemic index showed no improvement in insulin sensi-
tivity with any of the replacement diets  [59] . A similar 
lack of effect of SAFA substitution with MUFA or carbo-
hydrate on insulin sensitivity was observed in LIPGENE, 
another large randomized controlled trial performed in a 
pan-European population with metabolic syndrome  [67] . 
While others also found no evidence for the effect of di-
etary SAFA on insulin resistance or type 2 diabetes  [68] , 
a recent review of MUFA vs. SAFA on insulin sensitivity 
concluded that the strength of the evidence favoring 
MUFA over SAFA was probable because of the small 
number of participants, although neither the RISCK nor 
LIPGENE data were included in this analysis  [10] .
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 Liver and visceral fat are contributing factors to cardio-
metabolic risk and insulin resistance that can be modified 
through diet. Excess energy intake leads to fat accumula-
tion in liver and pancreas, which results in insulin resis-
tance, beta-cell dysfunction, hyperglycemia, dyslipidemia 
and vascular dysfunction  [69] . Compared with the con-
sumption of PUFA, high-SAFA intakes, mainly from 
palm oil, increased the accumulation of liver fat and vis-
ceral adipose tissue in young, normal-weight, overfed 
adults, while high PUFA intakes resulted in a nearly 3-fold 
increase in lean tissue compared with SAFA  [70] . Similar 
findings for liver fat were reported in abdominally obese 
participants who consumed either SAFA-rich (mainly 
butter) or n-6 PUFA-rich diets for 10 weeks  [71] . In addi-
tion, those who consumed the n-6 PUFA-rich diet showed 
a modest improvement in serum lipids and insulin levels 
without signs of inflammation or oxidative stress.
 Lovegrove concluded that the replacement of SAFA by 
PUFA is associated with a reduction in CVD (risk and 
mortality); replacement by PUFA or MUFA is associated 
with reduced lipid markers of cardiovascular risk; re-
placement by MUFA is associated with a reduction in 
other risk markers, such as SBP; and minimization of 
 trans fatty acid consumption benefits cardiovascular 
health. For dietary policy, it is important to use the total-
ity of evidence and multiple validated risk factors for 
mortality, and to translate nutrient intakes to foods and 
diets.
 Translating Dietary Recommendations to 
Food-Based Guidelines 
 Recent dietary guidelines have shifted their focus from 
single nutrients to foods and dietary patterns, partly to 
make recommendations more relevant to consumers, 
and partly from increased awareness of nutrient and food 
matrix interactions. Overall, healthy dietary patterns 
have been associated with a lower risk of most chronic 
diseases, although different approaches have been used to 
evaluate various food patterns  [72] . Discussing food-
based dietary guidelines, Ursula Schwab, University of 
Eastern Finland and Kuopio University Hospital,  Kuopio, 
Finland, explained that nutrient-based guidelines have 
been difficult to interpret by various users – the general 
population, food services, industry – and that people eat 
foods, not nutrients in isolation. It is also thought that it 
will be easier for people to adhere to a healthy food pat-
tern rather than nutrient-based recommendations as in-
dicated by recent studies  [73] .
 Food patterns have been studied in whole diet trials, 
such as those involving the Mediterranean  [74, 75] , Di-
etary Approaches to Stop Hypertension (DASH)  [76] , 
and healthy Nordic diets  [77] , and epidemiological stud-
ies  [72] and systematic reviews  [74, 75] . Whole diet trials 
have yielded similar and consistent conclusions on 
weight loss, reduction in CVD risk factors and improved 
longevity  [78] . Epidemiological studies have shown that 
dietary patterns rich in vegetables, fruits, nuts, whole 
grain cereals, fish, low-fat dairy products and vegetable 
oils, but low in refined cereals and sugar-rich products, 
red and processed meats are associated with a lower risk 
of most chronic diseases  [57, 79] . Systematic reviews 
have also found consistent benefits for similar diet pat-
terns and lower risks of incident or fatal CHD, breast 
cancer, all-cause mortality, CVD, cancer and neurode-
generative diseases  [31, 74, 80] . Several studies have re-
ported inverse association between various healthful di-
etary patterns or scores and risk of type 2 diabetes  [81–
83] .
 The DASH diet, described in 1997  [84] , was the first to 
combine several dietary modifications – increased fruits 
and vegetables, fat-free and low-fat dairy products, whole 
grain foods, poultry, fish, nuts and unsaturated fat – with 
reductions in dietary saturated fat, red meat, sweets, sug-
ar-sweetened beverages and salt. This diet resulted in sig-
nificant reductions in systolic and diastolic blood pres-
sures in hypertensive and normotensive participants over 
8 weeks compared with those consuming a controlled 
diet or a diet rich in fruits and vegetables only.
 In a review of 20 randomized controlled trials, Shirani 
et al.  [85] reported that a 16-week DASH diet significant-
ly reduced the fasting insulin concentration in patients 
with metabolic syndrome or dyslipidemia. The diet did 
not affect fasting glucose concentrations.
 Most studies of the Mediterranean diet in the context 
of type 2 diabetes and CVD have shown favorable effects 
on glycemic control and CVD risks, although there is 
some controversy about obesity  [86, 87] . A recent 4-year 
prospective cohort study examined the relationship be-
tween the Mediterranean diet and mortality in individu-
als with type 2 diabetes. The traditional Mediterranean 
diet was associated with a reduced risk of total and CVD 
mortality, independent of disease severity  [88] . Princi-
pal factor analysis suggested that the main contributors 
to the effect of diet were moderate alcohol, high intake 
of cereals, fruits and nuts and lower consumption of 
dairy and meat products. In an intervention study of the 
primary prevention of CVD in 418 high-risk individuals 
(PREDIMED), 2 variations of the Mediterranean diet, 
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supplementation with either virgin olive oil or nuts, 
were compared with a controlled diet of about similar 
fat content (41%En)  [89] . After 4 years, the incidence of 
type 2 diabetes was significantly lower in the 2 Mediter-
ranean diet groups, 10.1 and 11.0%, respectively com-
pared with 17.9% in the control group (40%En from fat). 
When the 2 diet groups were pooled, the risk of type 2 
diabetes was reduced by 52% compared with the control 
group. These changes occurred with no change in body 
weight or physical activity. In the full cohort of 7,447 
participants, the HRs for incident type 2 diabetes were 
0.60 (95% CI 0.43–0.85) and 0.82 (95% CI 0.61–1.10) for 
olive oil and nut-supplemented diets, respectively  [90] . 
The HRs for CVD events, including myocardial infarc-
tion, stroke or CVD death, were 0.70 (95% CI 0.53–0.91) 
and 0.70 (95% CI 0.53–0.94) for the 2 diet groups com-
pared with the control group. Several classical and 
emerging risk factors for CVD were also favorably af-
fected.
 Other healthy diet patterns modeled on the Mediter-
ranean diet, such as the healthy Nordic diet  [91] , have 
been developed to include local customs, food preferenc-
es and seasonality. Compared with the Mediterranean 
diet, the healthy Nordic diet includes rapeseed (canola) 
oil in place of olive oil; seasonal fruits, berries, root veg-
etables, pulses and nuts; vegetables with rapeseed oil salad 
dressings; consumption of fatty and other fish, game, 
whole grains and low-fat/non-fat milk products; and 
avoidance of butter, fatty dairy products, salted foods and 
red meat. In a randomized, controlled trial of 88 hyper-
cholesterolemic patients, those consuming the healthy 
Nordic diet for 18–24 weeks experienced significant re-
ductions in plasma TC, LDL-C, HDL-C, LDL-C:HDL-C 
ratio and apolipoprotein B compared with those on the 
control diet  [92] . In a different study, the healthy Nordic 
diet was associated with a significant reduction in obesi-
ty-related markers of inflammation, for example, hs-C-
reactive protein  [93] . The healthy Nordic diet was also 
associated with the down-regulation of genes involved in 
subcutaneous adipose tissue inflammation in obese indi-
viduals with the metabolic syndrome, independent of 
body weight change  [94] .
 The principles of the healthy Nordic diet were incor-
porated into a successful lifestyle intervention program to 
prevent type 2 diabetes in participants with impaired glu-
cose tolerance  [95] . Reduced consumption of total fat and 
SAFA with increased intake of dietary fiber and the addi-
tion of more than 4 h/week of physical activity resulted in 
a significant reduction in the risk of developing type 2 
diabetes in a median follow-up of 9 years (HR 0.61, 95% 
CI 0.48–0.79) compared to the control group  [95] . Six key 
Nordic foods formed the basis of the healthy Nordic food 
index, which was associated with an 18% lower total mor-
tality between the highest and lowest diet scores over 21 
years in Swedish women  [96] . However, the diet was not 
associated with CVD risk in the same cohort  [97] . In a 
Danish cohort, greater adherence to the healthy Nordic 
index was associated with a 25% lower risk of type 2 dia-
betes over 15 years in women and a 38% lower risk in men 
 [98] .
 Schwab concluded that the beneficial effects of health-
promoting diets have been shown to reduce the risk of 
CVD, type 2 diabetes and other chronic diseases in sev-
eral studies using different methods  [57, 72, 99] . Taking 
into account the local food culture also improves dietary 
adherence.
 In summary, symposium participants agreed that di-
etary guidelines should continue to recommend limiting 
dietary SAFA consumption, but at the same time empha-
size the importance of replacing SAFA with PUFA to re-
duce CVD risk. Replacement of  trans -fatty acids with 
PUFA has the most favorable effect on reducing LDL-C 
and therefore the CVD risk. Partial replacement of SAFA 
with MUFA may reduce some risk markers for CVD, but 
data are inconclusive about the effect of MUFA on the 
risk of CVD mortality. Participants agreed that dietary 
recommendations should shift their focus away from sin-
gle nutrients toward more healthy foods, such as whole 
grains, and dietary patterns, such as the Mediterranean, 
DASH and healthy Nordic diets, which promote health 
and reduce the risk of CVD, type 2 diabetes and other 
chronic diseases.
 In the general discussion, one audience member asked 
the presenters whether reducing the dairy fat intake was 
important if an individual was not obese. Lovegrove re-
sponded that it is recommended that dietary SAFA should 
be reduced to <10%En irrespective of body weight. How-
ever, despite the SAFA content, milk and dairy food con-
sumption has been associated with lower cardiometabol-
ic risk, possibly due to other dairy constituents, such as 
calcium and bioactive peptides  [100, 101] . Another par-
ticipant wondered whether an energy-reduced diet for 
overweight diabetic individuals should have more or less 
fat or carbohydrate. Schwab replied that the aim with 
such patients was not just weight loss, but also the overall 
improvement of the diet. The evidence suggests that dia-
betic patients can lose weight and improve their glycemic 
control with a variety of macronutrient interventions that 
include reduced energy intake, regular physical activity, 
education and support  [102] .
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